Test of Obrixtamig for DLL3-positive small cell lung tumors
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1 study tests different doses of obrixtamig in people with small cell lung cancer and other similar neuroendocrine tumors that test positive for a marker called DLL3. It may help doctors understand safety and the best dose, and possibly improve treatment options when standard therapy didn’t work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or spread cancer that cannot be cured with surgery or other curative treatment.
- Your tumor must be DLL3-positive based on lab testing of an old tissue sample or a new biopsy.
- You have already tried standard treatment and it didn’t work (or you can’t take it). For small cell types, standard treatment must have included platinum chemotherapy.
- You can do most normal activities (ECOG performance status 0–1).
- There must be at least one measurable tumor spot outside the brain (or specific conditions are met if cancer is in the brain).
- Your blood, liver, and kidney tests must be good enough for treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BL-M14D1 for people with certain types of advanced lung cancer or neuroendocrine tumors that have stopped responding to other treatments. It may be an option if your cancer has a specific marker called DLL3.
This trial tests a new drug called MP0712 that delivers radiation directly to cancer cells that have a marker called DLL3. It is for people with small cell lung cancer or other solid tumors that express DLL3, whose cancer has come back after prior treatments.
This trial tests whether adding a new drug, obrixtamig, to the usual first treatment for extensive-stage small cell lung cancer can help people live longer or slow the cancer's growth. The usual treatment is a combination of atezolizumab, carboplatin, and etoposide.
This trial tests a new treatment for advanced large-cell neuroendocrine cancer of the lung, a rare type of lung cancer. You may qualify if you've had one round of standard chemotherapy and your cancer has not improved with other treatments.
This trial tests a new combination of two drugs, Obrixtamig and ZL-1310, in people with advanced small cell lung cancer or other neuroendocrine cancers that have stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This Phase 2 study tests how different doses of BI 764532 affect people with small cell lung cancer or certain other neuroendocrine cancers. It may help shrink tumors and improve symptoms after standard treatments have stopped working.
Hear when a new Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.